Kamada Ltd KMDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KMDA is a good fit for your portfolio.
News
-
Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
-
Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
-
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Trading Information
- Previous Close Price
- $4.83
- Day Range
- $4.93–5.03
- 52-Week Range
- $4.08–6.53
- Bid/Ask
- $5.33 / $5.38
- Market Cap
- $287.40 Mil
- Volume/Avg
- 6,511 / 17,454
Key Statistics
- Price/Earnings (Normalized)
- 21.27
- Price/Sales
- 1.91
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 378
- Website
- https://www.kamada.com
Comparables
Valuation
|
Metric
|
KMDA
|
VIR
|
002007
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.27 | — | 22.40 |
Price/Book Value | 1.20 | 0.78 | 2.44 |
Price/Sales | 1.91 | 27.07 | 5.39 |
Price/Cash Flow | 10.71 | — | 27.56 |
Price/Earnings
KMDA
VIR
002007
Financial Strength
|
Metric
|
KMDA
|
VIR
|
002007
|
|---|---|---|---|
Quick Ratio | 1.98 | 12.22 | 2.68 |
Current Ratio | 4.25 | 12.90 | 4.01 |
Interest Coverage | 13.35 | — | 140.38 |
Quick Ratio
KMDA
VIR
002007
Profitability
|
Metric
|
KMDA
|
VIR
|
002007
|
|---|---|---|---|
Return on Assets (Normalized) | 4.07% | −19.57% | 10.96% |
Return on Equity (Normalized) | 6.47% | −24.29% | 15.42% |
Return on Invested Capital (Normalized) | 5.96% | −27.25% | 12.13% |
Return on Assets
KMDA
VIR
002007
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Zxxrwdtsz | Hzyh | $79.8 Bil | |||
| Merck KGaA ADR
MKKGY
| Tqmbjvsn | Jkwszxg | $70.0 Bil | |||
| Haleon PLC ADR
HLN
| Gdfvpbwl | Kfxrc | $37.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Jstwnqyzw | Jqfh | $18.4 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Xtzhwvgq | Vfm | $12.7 Bil | |||
| Viatris Inc
VTRS
| Bkkwbzgg | Llbz | $12.4 Bil | |||
| Catalent Inc
CTLT
| Fyqzpvxft | Mmdkgyx | $10.2 Bil | |||
| Perrigo Co PLC
PRGO
| Wsnsmblp | Ddgvt | $3.5 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Nrjtywpt | Pgkrtk | $3.4 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Wtzdhrs | Kzdkw | $2.8 Bil |